Page 17 - Read Online

Page 12 of 14 Atmaja et al. J Cancer Metastasis Treat 2021;7:xx https://dx.doi.org/10.20517/2394-4722.2021.66

9. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in
patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol
2015;16:293-300. DOI PubMed
10. Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in metastatic renal cell carcinoma: results from the International
Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2017;71:204-9. DOI PubMed
11. Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of
survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119:2999-3006. DOI
PubMed PMC
12. Yip S, Wells C, Moreira RB, Wong A, Heng DYC. Real world experience of immuno-oncology agents in metastatic renal cell
carcinoma: results from the IMDC. J Clin Oncol 2017;35:492.
13. Cella D, Grunwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with
nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019;20:297-310. DOI
PubMed PMC
14. Srigley JR, Delahunt B, Eble JN, et al. ISUP renal tumor panel. The International Society of Urological Pathology (ISUP) vancouver
classification of renal neoplasia. Am J Surg Pathol 2013;37:1469-89. DOI PubMed
15. Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
DOI PubMed PMC
16. Patard J-J, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633-
43. DOI PubMed
17. Sternberg CN, Calabro F, Bracarda S, et al. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma:
final results form an expanded-access trial. Oncology 2015;8:273-80. DOI PubMed
18. Chowdhury B, Porter EG, Stewart JC, et al. PBRM1 regulates the expression of genes involved in metabolism and cell adhesion in
renal clear cell carcinoma. PLoS One 2016;11:e0153718. DOI PubMed PMC
19. Hsieh JJ, Chen D, Wang PI, et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients
with metastatic renal cell carcinoma. Eur Urol 2017;71:405-14. DOI PubMed PMC
20. Carlo M, Manley B, Patil S, et al. Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell
carcinoma. Kidney Cancer 2017;1:49-56. DOI PubMed PMC
21. Creighton CJ. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007;26:4648-55. DOI
PubMed
22. Cao G, Wu X, Wang Z, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable,
intermediate and poor risk, respectively? BMJ Open 2020;10:eo34626. DOI PubMed PMC
23. Loewth R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell
growth control. Mol Cell 2002;10:457-68. DOI PubMed
24. Inoki K, Guan KL. Complexity of the TOR signalling network. Trends Cell Biol 2006;16:206-12. DOI
25. Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in
patients with metastatic renal cell carcinoma. Clin Cancer Res 2016;22:2445-52. DOI PubMed PMC
26. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J
Med 2018;378:1277-90. DOI PubMed PMC
27. Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803-13. DOI PubMed PMC
28. Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S)
for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Ann
Oncol 2017;28:V621-2. DOI
29. Mazza C, Escudier B, Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Ther Adv Med Oncol
2017;9:171-81. DOI PubMed PMC
30. Iacovelli, R, Nole F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-
analysis. Target Oncol 2016;11:143-48. DOI PubMed
31. RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin
Cancer Res 2007;13:709s-15s.
32. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Science 2018;59:801-6. DOI PubMed PMC
33. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals
distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63. DOI PubMed PMC
34. de Velasco G, Culhane AC, Fay AP, et al. Molecular subtypes improve prognostic value of International Metastatic Renal Cell
Carcinoma Database Consortium prognostic model. Oncol 2017;22:286-92. DOI PubMed PMC
35. Durinck S, Stawiski EW, Pavia-Jimenez A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma
subtypes. Nat Genet 2015;47:13-21. DOI PubMed PMC
36. Linehan WM, Spellman PT, Ricketts CJ, et al. Cancer genome atlas research network. Comprehensive molecular characterization of
papillary renal-cell carcinoma. N Engl J Med 2016;374:135-45. DOI PubMed PMC
37. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in
patients with papillary renal cell carcinoma. J Clin Oncol 2013;31:181-6. DOI PubMed PMC